| Literature DB >> 28834746 |
Maria Gato-Cañas1, Miren Zuazo1, Hugo Arasanz2, Maria Ibañez-Vea1, Laura Lorenzo1, Gonzalo Fernandez-Hinojal2, Ruth Vera3, Cristian Smerdou4, Eva Martisova4, Imanol Arozarena1, Claudia Wellbrock5, Diana Llopiz4, Marta Ruiz4, Pablo Sarobe4, Karine Breckpot6, Grazyna Kochan7, David Escors8.
Abstract
PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer cells from interferon (IFN) cytotoxicity and accelerates tumor progression. PDL1 inhibited IFN signal transduction through a conserved class of sequence motifs that mediate crosstalk with IFN signaling. Abrogation of PDL1 expression or antibody-mediated PDL1 blockade strongly sensitized cancer cells to IFN cytotoxicity through a STAT3/caspase-7-dependent pathway. Moreover, somatic mutations found in human carcinomas within these PDL1 sequence motifs disrupted motif regulation, resulting in PDL1 molecules with enhanced protective activities from type I and type II IFN cytotoxicity. Overall, our results reveal a mode of action of PDL1 in cancer cells as a first line of defense against IFN cytotoxicity.Entities:
Keywords: B7-H1; CD274; PD-L1; PD1; PDL1; immunotherapy; interferon; signal transduction
Mesh:
Substances:
Year: 2017 PMID: 28834746 DOI: 10.1016/j.celrep.2017.07.075
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423